ZA893971B - Aromatic steroid 5-alpha-reductase inhibitors - Google Patents

Aromatic steroid 5-alpha-reductase inhibitors

Info

Publication number
ZA893971B
ZA893971B ZA893971A ZA893971A ZA893971B ZA 893971 B ZA893971 B ZA 893971B ZA 893971 A ZA893971 A ZA 893971A ZA 893971 A ZA893971 A ZA 893971A ZA 893971 B ZA893971 B ZA 893971B
Authority
ZA
South Africa
Prior art keywords
alpha
beta
reductase inhibitors
steroid
preparation
Prior art date
Application number
ZA893971A
Other languages
English (en)
Inventor
Dennis Alan Holt
Alan Holt Dennis
Mark Alan Levy
Alan Levy Mark
Brian Walter Metcalf
Walter Metcalf Brian
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of ZA893971B publication Critical patent/ZA893971B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA893971A 1988-05-25 1989-05-25 Aromatic steroid 5-alpha-reductase inhibitors ZA893971B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19853488A 1988-05-25 1988-05-25

Publications (1)

Publication Number Publication Date
ZA893971B true ZA893971B (en) 1990-05-30

Family

ID=22733779

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA893971A ZA893971B (en) 1988-05-25 1989-05-25 Aromatic steroid 5-alpha-reductase inhibitors

Country Status (16)

Country Link
EP (1) EP0343954B1 (de)
JP (1) JP2675418B2 (de)
AT (1) ATE114665T1 (de)
AU (1) AU627466B2 (de)
CA (1) CA1331457C (de)
DE (1) DE68919537T2 (de)
DK (2) DK168295B1 (de)
ES (1) ES2065378T3 (de)
GR (1) GR3015135T3 (de)
HK (1) HK1006461A1 (de)
IE (1) IE68858B1 (de)
IL (1) IL91968A (de)
NO (1) NO174964C (de)
PT (1) PT90656B (de)
WO (1) WO1989011282A1 (de)
ZA (1) ZA893971B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
EP0638090A4 (de) * 1992-04-30 1995-10-04 Smithkline Beecham Corp 17-g(a) UND 17-g(b)-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-3-CARBONSAÜRE.
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
JPH07508034A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド １７−アミノ置換４−アザステロイド５α−レダクターゼ阻害剤
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
DE69329856D1 (de) * 1992-05-20 2001-02-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
JPH07508038A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ４−アザステロイドの１７−エーテル及びチオエーテル
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
AU6413594A (en) * 1993-03-24 1994-10-11 Merck & Co., Inc. Substituted 3-phenanthridinone derivatives as 5alpha-reductase inhibitors
JP3325026B2 (ja) * 1993-06-28 2002-09-17 メルク エンド カンパニー インコーポレーテッド ４−アザ−プレグナン５α−レダクターゼアイソザイム１阻害剤
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5430157A (en) * 1993-12-13 1995-07-04 Eli Lilly And Company Reduced phenanthrenes
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1107664B (de) * 1959-11-05 1961-05-31 Schering Ag Verfahren zur Herstellung neuer in 3-Stellung substituierter OEstratriene
US3622670A (en) * 1969-08-22 1971-11-23 American Home Prod Method of inducing ovulation
US4185101A (en) * 1977-08-11 1980-01-22 Schering Corporation 1,3,5(10),6,8-19-Nor-pregnapentaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
NO894065L (no) 1991-04-12
GR3015135T3 (en) 1995-05-31
CA1331457C (en) 1994-08-16
DK130393D0 (da) 1993-11-19
EP0343954B1 (de) 1994-11-30
ATE114665T1 (de) 1994-12-15
IL91968A (en) 1994-10-21
NO894065D0 (no) 1989-10-11
DK279790A (da) 1990-11-23
DE68919537T2 (de) 1995-05-11
PT90656A (pt) 1989-11-30
HK1006461A1 (en) 1999-02-26
DK169787B1 (da) 1995-02-27
DK279790D0 (da) 1990-11-23
WO1989011282A1 (en) 1989-11-30
EP0343954A3 (en) 1990-05-16
IE891732L (en) 1989-11-25
DK130393A (da) 1993-11-19
AU627466B2 (en) 1992-08-27
NO174964C (no) 1994-08-10
PT90656B (pt) 1994-10-31
JPH03504498A (ja) 1991-10-03
IE68858B1 (en) 1996-07-24
DK168295B1 (da) 1994-03-07
JP2675418B2 (ja) 1997-11-12
DE68919537D1 (de) 1995-01-12
AU3748789A (en) 1989-12-12
EP0343954A2 (de) 1989-11-29
ES2065378T3 (es) 1995-02-16
NO174964B (no) 1994-05-02

Similar Documents

Publication Publication Date Title
IE891732L (en) Aromatic steroid 5-ó-reductase inhibitors
GR3015039T3 (en) Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5alpha-reductase.
ZA899674B (en) Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-alpha-reductase
AU2960292A (en) Intermediates useful in the preparation of sulfonic acid substituted aromatic A ring analogues of steroidal synthetic compounds
GB8827988D0 (en) Chemical compounds
AU4257889A (en) Sulphonamido-phenylalkanoic acid derivatives having thromboxane A2 antagonist activity
NO881940D0 (no) 4-aminokinolin-derivater og deres anvendelse som legemidler.
HK1006841A1 (en) Substituted heterocyclic carboxylic acid amides their preparation and their use as medicaments
DE68909107D1 (de) 4-Amino-3-acylchinolin-Derivate und ihre Verwendung als Inhibitoren der Magensekretion.
ES538847A0 (es) Un derivado de fenilserina
DK259387A (da) Steroide forbindelser, der er virksomme mod kraeft og obesitet
HU678689D0 (en) Process for preparation of new carboximide-amide derivatives
GR860045B (en) Novel piperazine derivatives processes for production thereof and pharmaceutical compositions comprising said compounds as active ingredient
ZA885358B (en) Uricosuric composition
NZ228720A (en) Benzenesulphonamides and pharmaceutical compositions thereof